Clinical Trial Update: Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock [Phase 1, Phase 2]

View source ↗

Summary

A pharmacokinetic and biomarker study of pioglitazone conducted in adolescents with severe sepsis and septic shock completed Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Septic Shock

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Severe Sepsis, Septic Shock | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-09-02